Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.